Beta-receptor downregulation in congenital heart disease: a risk factor for complications after surgical repair?

Reiner Buchhorn1, Martin Hulpke-Wette, Wolfgang Ruschewski

  • 1Department of Pediatric Cardiology and Cardiothoracic Surgery, Georg-August-University Göttingen, Germany. rbuchho@gwdg.de

Insights

Congenital heart failure in children downregulates beta-receptors, impacting recovery after heart surgery. Therapy, including propranolol, influences this beta-receptor gene expression and postoperative outcomes.

Area of Science:

  • Pediatric Cardiology
  • Molecular Biology
  • Cardiothoracic Surgery

Background:

  • Congenital heart disease (CHD) in children often involves neurohormonal activation.
  • This activation can lead to downregulation of myocardial beta-receptors.
  • Such changes may significantly affect the postoperative course following cardiothoracic surgery.

Purpose of the Study:

  • To investigate the relationship between myocardial beta-receptor gene expression and postoperative outcomes in pediatric patients with CHD.
  • To assess the impact of heart failure therapy on beta-receptor levels.

Main Methods:

  • Myocardial biopsies were collected from 26 infants and children undergoing cardiac surgery.
  • Patients were grouped based on intensive care unit (ICU) stay duration (less than 7 days vs. more than 7 days, including early deaths).
  • Real-time polymerase chain reaction (PCR) was used to quantify beta1- and beta2-mRNA levels.

Main Results:

  • Children with shorter ICU stays (Group 1) showed significantly higher myocardial beta1- and beta2-receptor gene expression compared to those with longer ICU stays (Group 2).
  • Beta-receptor gene expression was lower in children receiving standard heart failure treatment versus those receiving additional propranolol.
  • These findings suggest a correlation between receptor expression and clinical outcomes.

Conclusions:

  • Downregulation of myocardial beta-receptors in pediatric congestive heart failure impacts postoperative recovery.
  • The degree of beta-receptor downregulation is influenced by the severity of heart failure and the type of therapy administered.
  • Targeting beta-receptor pathways may be crucial for improving outcomes in these patients.
Abstract